AstraZeneca PLC (AZNCF)
Other OTC - Other OTC Delayed price. Currency in USD
Add to watchlist
123.78+1.38 (+1.12%)
At close: 2:20PM EDT
| Previous close | 122.40 |
| Open | 123.51 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's range | 122.85 - 124.00 |
| 52-week range | 93.13 - 125.17 |
| Volume | 4,814 |
| Avg. volume | 2,887 |
| Market cap | 192.19B |
| Beta (5Y monthly) | 0.18 |
| PE ratio (TTM) | 43.11 |
| EPS (TTM) | 2.87 |
| Earnings date | N/A |
| Forward dividend & yield | 2.79 (2.26%) |
| Ex-dividend date | 12 Aug 2021 |
| 1y target est | N/A |
- Editor's pickYahoo Finance
'We're definitely not doing enough' to help global vaccinations: Former US Commerce Sec.
Former U.S. Commerce Sec. Gary Locke weighs in on the global vaccine equity debate and how the U.S. can better respond to the ongoing pandemic.
- Motley Fool
Can AstraZeneca's COVID Antibody Therapy Win Against Regeneron and Eli Lilly?
AstraZeneca (NASDAQ: AZN) awaits U.S. Emergency Use Authorization for its COVID-19 antibody therapy as a prophylaxis. In this Motley Fool Live video recorded on Oct. 13, Motley Fool contributors Keith Speights and Brian Orelli discuss how effective AstraZeneca might be in competing against antibody therapies marketed by COVID-19 antibody therapies already on the market.
- Yahoo Finance Video
Pfizer says vaccine is 90.7% effective in kids aged 5 to 11: BBG
Dr. Calvin Sun, The Monsoon Diaries Founder & CEO, Clinical Assistant Professor and Attending Physician in Emergency Medicine in NYC, joins Yahoo Finance to discuss the latest on the coronavirus pandemic.
© 2021 Verizon Media. All rights reserved.
